What is the generic name?

REGORAFENIB

What is the Trade Name for REGORAFENIB?

Stivarga

What are the Indications for REGORAFENIB?

• 1 INDICATIONS AND USAGE STIVARGA is a kinase inhibitor indicated for the treatment of patients with: ‚Ä¢ Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) ‚Ä¢ Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. ( 1.2 ) ‚Ä¢ Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (1.3) 1.1 Colorectal Cancer STIVARGA is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild- type, an anti-EGFR therapy. 1.2 Gastrointestinal Stromal Tumors STIVARGA is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. 1.3 Hepatocellular Carcinoma STIVARGA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

References: https://open.fda.gov/